ArticleEuropean radiology2026
Dual-energy CT liver fat fraction as prognostic imaging biomarker in critically ill patients.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between abdominal muscle mass measured by dual-source computed tomography and coronary artery calcification in patients with Type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Prediction of Occult Peritoneal Metastasis of Gastric Cancer Based on CT-Based Body Fat Analysis.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo analyze changes in the liver dual-energy CT fat fraction (liver DECT FF) at the intensive care unit (ICU), and its prognostic value. MATERIALS AND
methodsIntubated ICU patients were retrospectively included, who received two clinical DECT (CT1 and CT2) within a minimum interval of 10 days between 11/2019 and 12/2022. The liver DECT FF was determined by combining two regions of interest (ROI) in the right and one ROI in the left liver lobe (minimum area 3.6 cm
resultsOf 76 total patients, 43.4% were female (age 61 ± 12 years) and 97.4% received parenteral nutrition. In-hospital mortality was 60.8%. The liver DECT FF at CT1 was the only parameter associated with in-hospital mortality (hazard ratio: 1.15 [95% confidence interval: 1.07-1.24], p < 0.001), and a shorter ICU stay (-3.66 [-6.29 to -1.02] days, p < 0.007). DECT FF was not associated with ICU scoring systems. It did not relevantly change within a median of 8 days (3.3 ± 5.5% at CT1; 2.7 ± 4.3% at CT2, p = 0.315). Subset inter-observer reproducibility was good (ICC: 0.87 [0.66-0.95]).
conclusionThe liver DECT FF may serve as an independent prognostic imaging biomarker of mortality in critically ill patients, with a superior value to single-energy body composition parameters. KEY POINTS: Question Although the risk of liver steatosis is increased in critically ill patients, it is unknown if liver fat content, when quantified using DECT, is of prognostic value. Findings The liver DECT FF is associated with in-hospital mortality in critically ill patients. Clinical relevance The liver DECT FF may be superior for survival prognosis than single-energy CT body composition parameters of muscle and fat tissue at the ICU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.